| January 1998 | ||||
| Company | Type Of | Number Of | Amount | Investors; Placement Agents; |
| (Symbol) | Financing | Shares, Units | Raised (M) | Details (Date) |
| Or Warrants (M) | ||||
| Agritope Inc. | Private | 1.56S | $10.9 | Agritope, a recent spin-off of Epitope Inc., |
| (AGTO) | placements | raised $10.9M in private placements of | ||
| 1.34M shares of common stock and 0.21M | ||||
| shares of preferred stock, all at $7/share; the | ||||
| shares were issued to certain foreign | ||||
| investors in connection with the spin-off of | ||||
| Agritope as a public company (1/8) | ||||
| ChemTrak Inc. | Line of | -- | $1 | ChemTrak established a $1M fixed asset |
| (CMTR) | credit | lease line of credit with Pentech Financial | ||
| Services Inc.; ChemTrak has already drawn | ||||
| down 50% of the lease line, which is | ||||
| secured by the company's assets (1/7) | ||||
| Human Genome | Construction | -- | $40 | The Maryland Economic Development Corp. |
| Sciences Inc. (HGSI) | financing | (MEDCO) provided bond financing for the | ||
| construction of Human Genome Sciences' | ||||
| process development and production | ||||
| facility; key elements of the financing were | ||||
| also provided by First National Bank of Mary- | ||||
| land, the State of Maryland and Montgomery | ||||
| County; MEDCO is building the facility and | ||||
| will lease it to Human Genome Sciences (1/13) | ||||
| LXR Biotechnology | Private | 1.28S | $2.2 | This represents the final closing of LXR's |
| Inc. (LXR) | placement | $10M private placement (the 1st 2 closings | ||
| occurred in 12/97); in this closing, LXR sold | ||||
| 1.28M shares at $1.75 each to a group of in- | ||||
| vestors led by Grace Brothers Ltd.; the company | ||||
| will register the shares for resale (12/31; 1/5) | ||||
| MedImmune Inc. | Private | 1.7S | $66.3 | MedImmune sold 1.7M new shares of com- |
| (MEDI) | placement | mon stock at $39 each to institutional | ||
| investors BB Biotech, Investor AB and | ||||
| INVESCO Trust Co. in a self-managed pri- | ||||
| vate placement (1/13) | ||||
| Novavax Inc. | Private | ND | $6.5 | The company sold $6.5M in custom conver- |
| (NOX) | placement | tible preferred stock, which is convertible | ||
| into common stock at 100% of market for | ||||
| the 1st 90 days and at 94% thereafter; the com- | ||||
| pany has the option to call any unconverted | ||||
| stock at the end of 2 years and 3 years at | ||||
| certain set prices; the holders have option to | ||||
| put the preferred stock back to the company | ||||
| under certain conditions; Novavax will register | ||||
| the underlying shares for resale; Delta Oppor- | ||||
| tunity Fund Ltd. was the lead investor in this | ||||
| transaction; Diaz & Altschul Capital LLC acted | ||||
| as the placement agent (1/30) | ||||
| Oncor Inc. | Private | ND | $5 | Oncor sold $5M in preferred stock to undis- |
| (ONC) | placement | closed investors; the company will also | ||
| issue warrants to buy 0.125M shares at | ||||
| $5.16 each (1/9) | ||||
| Onyx | Private | 1.4S | $10 | Onyx sold 1.4M shares of common stock at |
| Pharmaceuticals | placement | $7.125/share to International Biotechnology | ||
| Inc. (ONXX) | Trust plc and Lombard Odier & Cie; the com- | |||
| pany will register the shares for resale (1/13) | ||||
| OraVax Inc. | Private | ND | $6.8 | The company raised $6.75M by selling |
| (ORVX) | placement | newly issued shares of 6% convertible pre- | ||
| ferred stock to a small group of investors; | ||||
| Cappello Capital Corp. acted as the place- | ||||
| ment agent (1/21) | ||||
| Ortec International | Exercise of | 1.08W | $10.8 | 1.08M of Ortec's Class A warrants, which |
| Inc. (ORTC) | warrants | were issued as part of the company's 1/96 | ||
| IPO unit offering, were exercised at a price | ||||
| of $10 each (1/8) | ||||
| Penederm Inc. | Line of | -- | $10 | Penederm entered an agreement with an |
| (DERM) | credit | unnamed investment group for an equity | ||
| line of credit for up to $10M through sales | ||||
| of its common stock over 2 years (at a dis- | ||||
| count to market) (1/21) | ||||
| Procept Inc. | Private | 2.4U | $1.2 | Procept raised $1.2M in the 1st closing of |
| (PRCT) | placement | its common stock unit offering, which is | ||
| intended to raise as much as $10M in | ||||
| 1Q:98; each unit consists of 1 common | ||||
| share and 1 5-year warrant to buy 1 share | ||||
| at $0.50; the company sold 2.4M units at | ||||
| $0.50 each to a combination of institutional | ||||
| and private investors; Procept will register | ||||
| the underlying shares for resale (1/30) | ||||
| TOTAL: $170.7M | ||||
| NOTES: | ||||
| ND = Not disclosed, reported and/or available; S = Shares; U = Units; W = Warrants | ||||
| The financings in this chart include loans, bridge financings and other interim measures as well as sales of business units, debt offerings, rights offerings, exercises of warrants, institutional offerings of registered stock and standard private placements. | ||||
